Our aim was to compare clinical outcomes for older people with COVID-19 in Wave 1 (W1) and 2 (W2).
Methods: All data, including the Clinical Frailty Scale (CFS), were collected for COVID-19 consecutive patients, aged ≥65, from thirteen hospitals, in W1 (February-June 2020) and W2 (October 2020-March 2021). The primary outcome was mortality (time to mortality and 28-day mortality). Data were analysed with multilevel Cox proportional hazards, linear and logistic regression models, adjusted for wave baseline demographic and clinical characteristics.
Results: Data from 611 people admitted in W2 were added to and compared with data collected during W1 (N=1340). Patients admitted in W2 were of similar age, median [IQR], W2= 79 [73-84]; W1=80 [74-86]; had a greater proportion of men (59.4% vs 53.0%); had lower 28-day mortality (29.1% vs 40.0%), compared to W1. For combined W1-W2 sample, W2 was independently associated with improved survival: time-to-mortality aHR= 0.78 (95%CI 0.65-0.93), 28-day mortality aOR=0.80 (95%CI 0.62-1.03). W2 was associated with increased length of hospital stay aHR=0.69 (95%CI 0.59-0.81). Patients in W2 were less
frail, CFS (adjusted mean difference [aMD]=-0.50, 95%CI -0.81, -0.18), as well as presented with lower CRP (aMD=-22.52, 95%CI -32.00, -13.04).
Conclusions: COVID-19 older adults in W2 were less likely to die than during W1. Patients presented to hospital during W2 were less frail and with lower disease severity and less likely to have renal decline.
|Number of pages||6|
|Journal||European Journal of Public Health|
|Early online date||23 Aug 2022|
|Publication status||Published - Oct 2022|
- older patients
- mortality rate
- predictors of death